Clinical Trial Update: A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing Dato-DXd to investigator's choice chemotherapy in operable or metastatic HR-positive, HER2-negative breast cancer; results were posted o…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Dato-DXd (datopotamab deruxtecan)

Snippet

Sponsor: AstraZeneca | Conditions: Breast Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2026-02-04